Imeik Technology Development Co

Imeik Technology Development Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Imeik Technology Development Co (300896.SZ) as of Oct 16, 2026 is 4,286.46 %. In the previous year, Operating Cash Flow to Debt Ratio was 3,724.65 % — a change of 15.08% (higher).

OCF/Debt

4,286.46 %

YoY

15.08%

Last updated:

Operating Cash Flow to Debt Ratio of Imeik Technology Development Co is 2024 4,286.46 % . Operating Cash Flow to Debt Ratio of Imeik Technology Development Co was 2023 3,724.65 % . It decreases by 15.08% higher compared to the previous year.

The Imeik Technology Development Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2017
1,530.16 CNY
Jan 1, 2021
1,959.16 CNY
Jan 1, 2022
2,000.26 CNY
Jan 1, 2023
3,724.65 CNY
Jan 1, 2024
4,286.46 CNY
The Imeik Technology Development Co OCF/Debt history
YEAROCF/DebtYoY
4,286.46 %+15.08%
3,724.65 %+86.21%
2,000.26 %+2.10%
1,959.16 %+28.04%
1,530.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co Ltd is a biotechnology company based in Beijing, China, operating within the healthcare sector. The company focuses on the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. It has established a product technology transformation platform for biomedical materials, including medical chitosan and polylactic acid. Imeik has successfully industrialized injection-type sodium hyaluronate series products and polydioxanone facial implants. Its self-developed products are primarily designed for the repair of facial and neck skin folds, with clinical applications spanning medical cosmetology, surgical repair, and the treatment of metabolic diseases. The company went public on the Shenzhen Stock Exchange on September 28, 2020, with ticker 300896.SZ and ISIN CNE100004868. Imeik currently employs 713 full-time staff and operates exclusively within the Chinese market. Its website is www.imeik.net, providing information on its products and services. The company emphasizes the development and transformation of biomedical materials, aiming to advance biomedicine through its specialized focus on recombinant proteins and peptides. It has developed a range of products that address specific medical and cosmetic needs, contributing to its position in the healthcare industry. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Operating Cash Flow to Debt Ratio of Imeik Technology Development Co is 4,286.46 % in 2024.

Operating Cash Flow to Debt Ratio of Imeik Technology Development Co changed from 3,724.65 % to 4,286.46 %, representing a 15.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Imeik Technology Development Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Imeik Technology Development Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Imeik Technology Development Co